1. Home
  2. FT vs EDIT Comparison

FT vs EDIT Comparison

Compare FT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin Universal Trust

FT

Franklin Universal Trust

HOLD

Current Price

$8.02

Market Cap

199.8M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.19

Market Cap

202.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FT
EDIT
Founded
1988
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Trusts Except Educational Religious and Charitable
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
199.8M
202.1M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
FT
EDIT
Price
$8.02
$2.19
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$4.50
AVG Volume (30 Days)
63.0K
1.9M
Earning Date
01-01-0001
03-04-2026
Dividend Yield
7.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$46,383,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$5.97
$0.91
52 Week High
$7.23
$4.54

Technical Indicators

Market Signals
Indicator
FT
EDIT
Relative Strength Index (RSI) 47.12 48.83
Support Level $8.04 $1.92
Resistance Level $8.05 $2.43
Average True Range (ATR) 0.08 0.15
MACD 0.00 0.03
Stochastic Oscillator 38.46 51.84

Price Performance

Historical Comparison
FT
EDIT

About FT Franklin Universal Trust

Franklin Universal Trust is a closed-end management investment company focused on providing high current income while preserving capital. Its secondary objective is to achieve income growth through dividend increases and capital appreciation. The fund invests in two asset classes: high-yield bonds and utility stocks. It applies fundamental research to build a diversified high-yield bond portfolio and targets utility companies with attractive dividend yields and a history of increasing dividends.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: